• CytomX Therapeutics’ Q3 2026 revenue fell 72% year over year to $1.7 million.
• Operating expenses rose 16% year over year to $25.2 million.
• Quarter-end cash, cash equivalents and investments totaled $348 million, with expected cash runway into the second half of 2028.
• A Varseta-M colorectal cancer monotherapy data update is expected in January 2027; a first registrational study could begin in 1H 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytomX Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-449787), on November 05, 2026, and is solely responsible for the information contained therein.